Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression

Journal of Hypertension

Volumn 30, Issue 1, 2012, Pages 204-209

  Cerezo, Cesar ^a   Ruilope, Luis M ^a,b   Segura, Julian ^a   Garcia Donaire, Jose A ^a   De La Cruz, Juan J ^b   Banegas, Jose R ^b   Waeber, Bernard ^c   Rabelink, Ton J ^d   Messerli, Franz H ^e  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

albuminuria; cardiovascular risk; chronic renin angiotensin system suppression

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

EID: 83455237403     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834d9e0f     Document Type: Article

References (30)

1. De Jong PE, Gansevoort RT, Bakker SJ. Macroalbuminuria and microalbuminuria do both predict renal and cardiovascular events with similar strength? J Nephrol 2007; 20:375-380. (Pubitemid 350081489)
2. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, et al. Risk prediction is improved by adding markers of subclinical damage to SCORE. Eur Heart J 2010; 31:883-891.
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187. (Pubitemid 46924065)
4. American Diabetes Association. Executive summary: standards of medical care in diabetes: 2010. Diabetes Care 2010; 33 (Suppl 1):S4-S10.
5. Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313:1617-1620. (Pubitemid 16155665)
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis 2002; 39 (Suppl 1): S76-S110.
7. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
8. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al., Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
9. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS trial study group. N Engl J Med 1987; 316:1429-1435.
10. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327:669-677.
11. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensinconverting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368:581-588. (Pubitemid 44209181)
12. SolomonSD, Rice MM,AJablonski K, Jose P,Domanski M, Sabatine M, et al.; Prevention of Events with ACE inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 2006; 114:26-31. (Pubitemid 44305271)
13. Segura J, Campo C, Gil P, Roldán C, Vigil L, Rodicio JL, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15:1616-1622. (Pubitemid 38679687)
14. Gustafsson F, Segura J, Ruilope LM. How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta blockers for hypertension, diabetes or coronary disease? J Hypertens 2010; 28:1595-1598.
15. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al., ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
16. Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al., ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372:547-553.
17. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al., LIFE substudy. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22:1805-1811. (Pubitemid 39141974)
18. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, et al., Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensinreceptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961. (Pubitemid 39447136)
19. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. NEngl J Med 2004; 351:1941-1951.
20. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al., ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364:907-917.
21. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63:225-232. (Pubitemid 35463925)
22. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39:794-798. (Pubitemid 34252878)
23. Menne J, Chatzikyrkou C, Haller H. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade. J Hypertens 2010; 28:1983-1994.
24. Ruilope LM, Bakris GL. Renal function and target organ damage in hypertension. Eur Heart J 2011; 32:1599-1604.
25. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355:253-259.
26. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk. Ann Intern Med 2011; 154:310-318.
27. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559. (Pubitemid 351522739)
28. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358:2433-2446. (Pubitemid 351793017)
29. Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20:2641-2650.
30. Werner C, Pö ss J, Böhm M. Optimal antagonism of the renin-angiotensinaldosterone system: do we need dual or triple therapy? Drugs 2010; 70:1215-1230.